Cerecero-García Diego, Pineda-Antunez Carlos, Alexander Lily, Cameron Drew, Martinez-Silva Gisela, Obure Carol Dayo, Marseille Elliot, Vu Lung, Kahn James G, Vassall Anna, Gomez Gabriela, Bollinger Lori, Levin Carol, Bautista-Arredondo Sergio
National Institute of Public Health, Cuernavaca, Mexico.
HIV AIDS TB Research Consortium CISIDAT, Cuernavaca, Mexico.
Afr J AIDS Res. 2019 Dec;18(4):297-305. doi: 10.2989/16085906.2019.1688362.
To estimate facility-level average cost for ART services and explore unit cost variations using pooled facility-level cost estimates from four HIV empirical cost studies conducted in five African countries . Through a literature search we identified studies reporting facility-level costs for ART programmes. We requested the underlying data and standardised the disparate data sources to make them comparable. Subsequently, we estimated the annual cost per patient served and assessed the cost variation among facilities and other service delivery characteristics using descriptive statistics and meta-analysis. All costs were converted to 2017 US dollars ($). We obtained and standardised data from four studies across five African countries and 139 facilities. The weighted average cost per patient on ART was $251 (95% CI: 193-308). On average, 46% of the mean unit cost correspond to antiretroviral (ARVs) costs, 31% to personnel costs, 20% other recurrent costs, and 2% to capital costs. We observed a lot of variation in unit cost and scale levels between countries. We also observed a negative relationship between ART unit cost and the number of patients served in a year. Our approach allowed us to explore unit cost variation across contexts by pooling ART costs from multiple sources. Our research provides an example of how to estimate costs based on heterogeneous sources reconciling methodological differences across studies and contributes by giving an example on how to estimate costs based on heterogeneous sources of data. Also, our study provides additional information on costs for funders, policy-makers, and decision-makers in the process of designing or scaling-up HIV interventions.
利用在五个非洲国家开展的四项艾滋病毒实证成本研究中的综合设施层面成本估计,来估算抗逆转录病毒治疗(ART)服务的设施层面平均成本,并探讨单位成本差异。通过文献检索,我们确定了报告ART项目设施层面成本的研究。我们索取了基础数据,并对不同的数据来源进行标准化处理,使其具有可比性。随后,我们估算了每位接受治疗患者的年度成本,并使用描述性统计和荟萃分析评估了各设施之间的成本差异以及其他服务提供特征。所有成本均换算为2017年美元($)。我们获取并标准化了来自五个非洲国家139个设施的四项研究的数据。接受ART治疗患者的加权平均成本为251美元(95%置信区间:193 - 308美元)。平均而言,平均单位成本的46%对应抗逆转录病毒药物(ARVs)成本,31%对应人员成本,20%对应其他经常性成本,2%对应资本成本。我们观察到各国之间在单位成本和规模水平上存在很大差异。我们还观察到ART单位成本与一年中接受治疗的患者数量之间存在负相关关系。我们的方法使我们能够通过汇总多个来源的ART成本来探讨不同背景下的单位成本差异。我们的研究提供了一个如何基于异质来源估算成本的示例,协调了各项研究之间的方法差异,并通过给出一个基于异质数据来源估算成本的示例做出了贡献。此外,我们的研究为资助者、政策制定者和决策者在设计或扩大艾滋病毒干预措施过程中提供了有关成本的更多信息。